ARTS-011 / Allorion Therap - LARVOL DELTA

Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. (PubMed, Br J Pharmacol) - P1 | "ARTS-011 is a promising oral Tyk2 inhibitor with an acceptable safety profile and potential for once-daily dosing. These results support further clinical development of ARTS-011 in patients with inflammatory and autoimmune diseases."

Clinical • First-in-human • Journal • P1 data • PK/PD data • Immunology • TYK2

ARTS-011-101: Safety and Pharmacokinetic Study of ARTS-011 in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Allorion Therapeutics Inc | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Mar 2024

Trial completion • Trial completion date

Safety and Pharmacokinetic Study of ARTS-011 in Chinese Healthy Volunteers (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Allorion Therapeutics Inc

New P1 trial